David A. Braun, MD, PhD

David A. Braun, MD, PhD, discusses immune defects in patients with chromophobe RCC vs clear cell RCC.

Dr Braun discusses molecular factors that contribute to exceptional immune checkpoint inhibition responses among patients with renal cell carcinoma.

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.

David A. Braun, MD, PhD, discusses the potential use of protein glycosylation as a biomarker of response in renal cell carcinoma.

David A. Braun, MD, PhD, discusses advancements in biomarker development that could help guide treatment decisions in renal cell carcinoma.

David A. Braun, MD, PhD, discusses the role of biomarkers in guiding adjuvant treatment strategies for renal cell carcinoma.

David A. Braun, MD, PhD, discusses the variety of therapies available for the treatment of patients with kidney cancer.

David Braun, MD, PhD discusses the selection of immune checkpoint inhibitor use in clear cell renal cell carcinoma

David Braun, MD, PhD, discusses findings from the molecular analysis of the HCRN GU16-260-Cohort A study.

David A. Braun, MD, PhD, discusses considerations with immunotherapy-based regimens in patients with renal cell carcinoma.

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.

Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.

The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.

David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.

Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.

Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.

David A. Braun, MD, PhD, discusses the enrichment of SLAMF7-positive, CD8-positive T-cells and their role on nivolumab resistance in clear cell and non–clear cell renal cell carcinoma.

David A. Braun, MD, PhD, discusses unanswered questions regarding the utility of PD-1 blockade in advanced renal cell carcinoma.